(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 149.8MM | +87% |
Gross Profit | 118.3MM | +86% |
Cost Of Revenue | 31.5MM | +89% |
Operating Income | 13.2MM | - |
Operating Expenses | 105.1MM | - |
Net Income | 10.5MM | - |
R&D | 21.2MM | +85% |
G&A | 105.1MM | +83% |
Marketing | 49MM | +84% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have been sold globally.1
STAAR Surgical Company ( NASDAQ:STAA ) shareholders should be happy to see the share price up 25% in the last month...
West Pharmaceutical (WST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day March Small-Cap Conference taking place Wednesday and Thursday, March 13-14, ...
LAKE FOREST, Calif., March 12, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Arthur Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific for Boston Scientific, and Wei Jiang, retired Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC, to its Board of Directors, e
LAKE FOREST, Calif., March 06, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors at the following conferences:
STAAR Surgical Company (NASDAQ:STAA) Q4 2023 Earnings Call Transcript February 26, 2024 STAAR Surgical Company beats earnings expectations. Reported EPS is $0.24, expectations were $0.19. STAA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, ladies and gentlemen. Thank […]
The headline numbers for Staar Surgical (STAA) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Staar Surgical (STAA) delivered earnings and revenue surprises of 26.32% and 0.30%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Continued Profitability with Double-Digit Sales Growth and Strong ICL Sales Performance